Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Antimicrobial therapy administered during hospitalization in 3463 patients

From: Prospective Observational Study on acute Appendicitis Worldwide (POSAW)

Patients receiving antibiotics N = 3463 (%)
Metronidazole or ornidazole 2021 (58.2%)
Third-generation cephalosporins 1280 (37.0%)
Second-generation cephalosporins 598 (17.2%)
Penicillins + beta lactams-inhibitors 500 (14.4%)
First-generation cephalosporins 437 (12.6%)
Second-generation quinolones 304 (8.8%)
Aminoglycosides 289 (8.3%)
Ureidopenicillins + beta lactams-inhibitors 130 (3.7%)
Aminopenicillins 61 (1.8%)
Carbapenems 58 (1.7%)
Third-generation cephalosporins + beta lactams-inhibitors 52 (1.5%)
Third-generation quinolones 18 (0.5%)
Fourth-generation cephalosporins 12 (0.3%)
Others 15 (0.4%)
  1. n number of patients receiving antibiotic treatment